Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia

摘要: The BCR-ABL tyrosine kinase produced by the t(9;22)(q34;q11) translocation, also known as Philadelphia chromosome, is initiating event in chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic (ALL). Targeting of with inhibitors (TKIs) has resulted rapid clinical responses vast majority patients CML chromosome+ ALL. However, long-term use TKIs occasionally results emergence therapy resistance, part through selection clones mutations domain. We present here an overview current practice monitoring for such mutations, including methods used, laboratory criteria triggering mutational analysis, guidelines reporting mutations. alsopresent a proposal public database correlating status vitro vivo to different aid interpretation mutation studies.